-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...

-The Times of India MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market. Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster...

-Reuters Global drugmakers, battered by recent intellectual property decisions in the country, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country. Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country. "Big Pharma is nervous because nothing has gone in their favour in the...

-The Times of India MUMBAI: The Union government and regulatory bodies appear to be serious in ending the pharma-doctor nexus and curb unethical marketing practices. In its latest effort, the Medical Council of India has directed doctors, hospitals and medical colleges to prescribe generic medicines as far as possible. Generic medicines are more affordable versions of Branded Medicines sold by companies. In its directive dated January 21 to the principals of medical...

-The Economic Times The Union Cabinet has okayed a new price-control formula for pharmaceuticals, which seeks to cap prices at the arithmetic average of all drugs with more than 1% market share in any therapeutic segment that is to be brought under price control. Given that the existing system of fixing prices of select drugs is on the basis of costs, which is rigid, intrusive and prone to manipulation as well,...